Lack of MGMT promotor hypermethylation and high expression of MGMT were observed in 75% (total=12) of recurrent anaplastic ependymomas, which theoretically favored the trial of temozolomide in PSAE patients (38). This evidence concerns the gene MGMT and anaplastic ependymoma.